Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis

• Hauptverfasser: Takeshi Nakahara (VerfasserIn), Hiroyuki Murota (VerfasserIn), Miyuki Matsukawa (VerfasserIn), Hiroe Takeda (VerfasserIn), Yilong Zhang (VerfasserIn), Tomohiro Kondo (VerfasserIn)
• Format: Buch
• Veröffentlicht: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Background Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe in phases 2 and 3 clinical trials in Japan. However, there are no head-to-head trials comparing the...